Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or refractory acute myeloid leukemia (AML) is a type of blood cancer that returns after treatment or does not respond to initial therapy, leading to severe health challenges.
Acute Myeloid Leukemia: JNJ-89853413 Study
We are testing a new treatment for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The goal is to evaluate its safety and how it may help those who have not responded to other therapies.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells, often leading to ineffective blood production and increased risk of leukemia.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Clinica Universidad De Navarra
Hematology
Barañáin, Spain
Hospital Clinic De Barcelona
Hematology
El Altet, Spain
Hospital Universitario Fundacion Jimenez Diaz
Hematology
Madrid, Spain
Sponsor: Janssen Cilag International
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.